天眼查显示，近日，上海安科华泽药业有限公司成立，法定代表人为CHOU TA WEI，注册资本10000万 人民币，由安徽安科生物工程（集团）股份有限公司全资持股。 经营范围含许可项目：药品零售；药品进出口；药品批发；药用辅料销售；药品委托生产；药品生产 【分支机构经营】；药品生产（不含中药饮片的蒸、炒、炙、煅等炮制技术的应用及中成药保密处方产 品的生产）【分支机构经营】。（依法须经批准的项目，经相关部门批准后方可开展经营活动，具体经 营项目以相关部门批准文件或许可证件为准）自主展示（特色）项目：技术服务、技术开发、技术咨 询、技术交流、技术转让、技术推广；会议及展览服务；化妆品批发；电子产品销售。 序号股东名称持股比例1安徽安科生物工程（集团）股份有限公司100% 企业名称上海安科华泽药业有限公司法定代表人CHOU TA WEI注册资本10000万人民币国标行业制造业 >医药制造业>化学药品制剂制造地址中国（上海）自由贸易试验区盛荣路388弄17号2楼企业类型有限 责任公司（自然人投资或控股的法人独资）营业期限2025-12-12至无固定期限登记机关自由贸易试验区 市场监管局 来源：市场资讯 ...

Core Insights - The precision medicine sector experienced a slight increase of 0.53% on December 12, with BGI Genomics leading the gains [1] - The Shanghai Composite Index closed at 3889.35, up 0.41%, while the Shenzhen Component Index closed at 13258.33, up 0.84% [1] Stock Performance - BGI Genomics (688114) saw a closing price of 64.50, with a significant increase of 7.68% and a trading volume of 86,400 shares, resulting in a transaction value of 540 million yuan [1] - Other notable performers included: - BGI (300676) with a closing price of 45.71, up 3.86% [1] - Wondfo Biotech (300685) at 21.55, up 1.41% [1] - Berry Genomics (000710) at 11.18, up 0.72% [1] - WuXi AppTec (603259) at 94.05, up 0.70% [1] Capital Flow - The precision medicine sector saw a net outflow of 1.022 billion yuan from institutional investors, while retail investors contributed a net inflow of 586 million yuan [2] - The capital flow for specific stocks included: - BGI Genomics (688114) had a net inflow of 22.93 million yuan from institutional investors [3] - Anke Bio (300009) experienced a net inflow of 3.38 million yuan from institutional investors [3] - However, ST Xiangxue (300147) faced a net outflow of 2.93 million yuan from institutional investors [3]

Core Viewpoint - Anke Biopharma aims for high-quality development through innovation, focusing on a strategic layout that includes biopharmaceuticals, traditional Chinese medicine, and precision medicine, while actively exploring mRNA technology, ADC, oncolytic viruses, cell therapy, and gene therapy [2][4]. Financial Performance - In the first three quarters of 2025, Anke Biopharma reported a revenue of 1.963 billion yuan, representing a year-on-year increase of 2.15%. The net profit attributable to shareholders was 551 million yuan, a decrease of 6.48%. R&D expenses amounted to 145 million yuan, reflecting a year-on-year growth of approximately 12.4% [3]. Strategic Development - Anke Biopharma's strategic goal is to achieve a valuation, revenue, and profit of 10 billion yuan each, encapsulated in the phrase "100 billion Anke, 100-year Anke" [2]. - The company has a history of innovation since its establishment, transitioning from a state-owned enterprise to a publicly listed company, with significant reforms occurring in 1995, 1996, and 2000 [3]. R&D Focus - Anke Biopharma invests nearly 10% of its annual revenue into R&D, emphasizing innovation in product development, talent acquisition, and research investment [4]. - The company’s product portfolio includes biopharmaceuticals, traditional Chinese medicine, small molecule drugs, peptide drugs, and cell immunotherapy [4]. AI Integration - The integration of AI in drug development is highlighted, with potential to significantly reduce the time for drug discovery and clinical research, from five years to one year for large molecules and from five to eight years to three to five years for clinical studies [5]. - The establishment of the Anke Biopharma (Shanghai) Innovation Research Institute aims to enhance R&D capabilities and attract high-end talent, addressing current R&D bottlenecks and fostering innovation in drug development [5].

Group 1 - On December 5, a total of 9 companies had their restricted shares unlocked, with a total unlock volume of 286 million shares, amounting to a market value of 8.268 billion yuan based on the latest closing price [1] - The companies with the highest unlock volumes include Donghua Technology, Jiachih Technology, and Anke Biology, with unlock shares of 164 million, 104 million, and 7.8776 million respectively [1] - In terms of unlock market value, Jiachih Technology, Donghua Technology, and Zhongce Rubber lead with market values of 6.023 billion, 1.797 billion, and 148 million yuan respectively [1] Group 2 - The companies with the highest unlock ratios relative to total share capital include Jiachih Technology, Donghua Technology, and Fua'an Co., with unlock ratios of 25.97%, 23.1%, and 2.07% respectively [1]

Core Viewpoint - Anke Bio (300009) announced that its affiliated companies, Boshengji Pharmaceutical Technology (Suzhou) Co., Ltd. and Boshengji Anke Cell Technology Co., Ltd., have received acceptance for a clinical trial application for PA3-17 injection targeting relapsed/refractory T-cell acute lymphoblastic leukemia/lymphoma (R/R T-ALL/LBL) [1] Group 1 - The PA3-17 injection is the world's first autologous CAR-T cell therapy product targeting CD7 that has received clinical trial approval [1] - The product was included in the list of breakthrough therapies by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) in August [1]

Core Viewpoint - Anke Biotech (300009.SZ) announced that its affiliated companies, Boshengji Pharmaceutical Technology (Suzhou) Co., Ltd. and Boshengji Anke Cell Technology Co., Ltd., have received acceptance for a clinical trial application for the PA3-17 injection targeting relapsed/refractory T-cell acute lymphoblastic leukemia/lymphoma (R/RT-ALL/LBL) in children and adolescents from the National Medical Products Administration [1] Group 1 - Anke Biotech's affiliated companies are involved in the development of PA3-17 injection [1] - The clinical trial application for PA3-17 has been accepted, indicating progress in the drug development process [1] - The targeted indication for the clinical trial is specifically for children and adolescents suffering from R/RT-ALL/LBL [1]

格隆汇12月4日｜安科生物公告，公司参股公司博生吉医药科技（苏州）有限公司、博生吉安科细胞技 术有限公司自主研发的PA3-17注射液新增"针对儿童和青少年复发/难治性T淋巴母细胞白血病/淋巴瘤 （R/RT-ALL/LBL）"的适应症临床试验申请已获受理。本次新增适应症临床试验申请获得受理仅是新药 研发的阶段性成果，能否获得国家药品监督管理局批准进行临床试验、上市尚存在不确定性，敬请广大 投资者谨慎决策，注意防范投资风险。 ...

安科生物公告，参股公司博生吉医药科技（苏州）有限公司、博生吉安科细胞技术有限公司自主研发的 PA3-17注射液新增"针对儿童和青少年复发/难治性T淋巴母细胞白血病/淋巴瘤（R/RT-ALL/LBL）"的适 应症临床试验申请已获受理，并收到国家药品监督管理局行政许可文书《受理通知书》，受理号为： CXSL2501040。 ...

本公司及董事会全体成员保证公告内容真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏。 近日，安徽安科生物工程（集团）股份有限公司（以下简称"公司"）参股 公司博生吉医药科技（苏州）有限公司、博生吉安科细胞技术有限公司（以下简 称"博生吉安科"）自主研发的PA3-17注射液新增"针对儿童和青少年复发/难 治性T淋巴母细胞白血病/淋巴瘤（R/R T-ALL/LBL）"的适应症临床试验申请已 获受理，并收到国家药品监督管理局行政许可文书《受理通知书》，受理号为： CXSL2501040。具体情况如下： PA3-17注射液是博生吉安科自主研发的全球首款获得新药临床试验批准的 靶向CD7的自体CAR-T细胞治疗产品，已于2025年8月被国家药品监督管理局药 品审评中心（CDE）纳入突破性治疗品种名单。该产品目前正在开展针对成人复 发/难治性T淋巴母细胞白血病/淋巴瘤（R/R T-ALL/LBL）患者的关键性II期临床 试验，具体内容详见公司于巨潮资讯网披露的《关于参股公司PA3-17注射液获准 进入关键性II期临床试验的公告》（公告编号：2025-051）。 本次为PA3-17注射液新增用于儿童和青少年复发/难 ...

Core Viewpoint - Anke Biological has experienced a decline in stock price recently, with a year-to-date increase of 15% but a notable drop in the last 20 and 60 days [1][2] Financial Performance - For the period from January to September 2025, Anke Biological reported a revenue of 1.963 billion yuan, representing a year-on-year growth of 2.15%. However, the net profit attributable to shareholders decreased by 6.48% to 551 million yuan [2] - The company has distributed a total of 2.662 billion yuan in dividends since its A-share listing, with 1.252 billion yuan distributed in the last three years [3] Stock Market Activity - As of December 3, Anke Biological's stock price was 9.65 yuan per share, with a market capitalization of 16.14 billion yuan. The stock has seen a trading volume of 155 million yuan and a turnover rate of 1.31% [1] - The stock has been on the "龙虎榜" (a list of stocks with significant trading activity) once this year, with a net purchase of 193 million yuan on July 31 [1] Shareholder Information - As of November 10, the number of shareholders for Anke Biological was 76,100, a decrease of 1.10% from the previous period. The average number of circulating shares per shareholder increased by 1.11% to 16,062 shares [2] - The top ten circulating shareholders include Hong Kong Central Clearing Limited and several investment funds, with notable changes in their holdings [3]